OBJECTIVE: To determine the prevalence of thrombotic events and all-cause mortality in men older than 65 years with hypogonadism treated with testosterone therapy (TST). PATIENTS AND METHODS: We retrospectively reviewed the charts of 217 hypogonadal men >65 years. We compared men who received TST (n = 153) to hypogonadal men (n = 64) who did not receive TST. We evaluated all-cause mortality, prevalence of myocardial infarction (MI), transient ischemic attack (TIA), cerebrovascular accident (CVA or "stroke"), and deep vein thrombosis/pulmonary embolism (DVT/PE). All events were verified by contacting patients. We excluded men with previous thrombotic events, men previously on androgen deprivation therapy, and men who had used TST before age of 65 years. RESULTS: Median age and Charlson Comorbidity Index of men on TST (74y; 5.1) was similar to hypogonadal men not on TST (73y, P = .48; 5.3, P = .36). Median follow-up was 3.8 vs 3.5 years (TST vs no TST). No man on TST died, whereas 5 hypogonadal men who did not receive TST died (P = .007). There were 4 thrombotic events (1 MI, 2 CVA/TIA, and 1 PE) in men who received TST and 1 event (CVA/TIA) among men who did not receive TST (P = .8). All events (1 death, 6-month follow-up) occurred at least after 2 years of follow-up. CONCLUSION: There was increased all-cause mortality in hypogonadal men not treated with testosterone compared to men who received TST. There was no difference in prevalence of MI, TIA/CVA, or PE between patients treated with testosterone and hypogonadal men not treated with testosterone.
OBJECTIVE: To determine the prevalence of thrombotic events and all-cause mortality in men older than 65 years with hypogonadism treated with testosterone therapy (TST). PATIENTS AND METHODS: We retrospectively reviewed the charts of 217 hypogonadal men >65 years. We compared men who received TST (n = 153) to hypogonadal men (n = 64) who did not receive TST. We evaluated all-cause mortality, prevalence of myocardial infarction (MI), transient ischemic attack (TIA), cerebrovascular accident (CVA or "stroke"), and deep vein thrombosis/pulmonary embolism (DVT/PE). All events were verified by contacting patients. We excluded men with previous thrombotic events, men previously on androgen deprivation therapy, and men who had used TST before age of 65 years. RESULTS: Median age and Charlson Comorbidity Index of men on TST (74y; 5.1) was similar to hypogonadal men not on TST (73y, P = .48; 5.3, P = .36). Median follow-up was 3.8 vs 3.5 years (TST vs no TST). No man on TST died, whereas 5 hypogonadal men who did not receive TST died (P = .007). There were 4 thrombotic events (1 MI, 2 CVA/TIA, and 1 PE) in men who received TST and 1 event (CVA/TIA) among men who did not receive TST (P = .8). All events (1 death, 6-month follow-up) occurred at least after 2 years of follow-up. CONCLUSION: There was increased all-cause mortality in hypogonadal men not treated with testosterone compared to men who received TST. There was no difference in prevalence of MI, TIA/CVA, or PE between patients treated with testosterone and hypogonadal men not treated with testosterone.
Authors: Kay-Tee Khaw; Mitch Dowsett; Elizabeth Folkerd; Sheila Bingham; Nicholas Wareham; Robert Luben; Ailsa Welch; Nicholas Day Journal: Circulation Date: 2007-11-26 Impact factor: 29.690
Authors: Shehzad Basaria; Andrea D Coviello; Thomas G Travison; Thomas W Storer; Wildon R Farwell; Alan M Jette; Richard Eder; Sharon Tennstedt; Jagadish Ulloor; Anqi Zhang; Karen Choong; Kishore M Lakshman; Norman A Mazer; Renee Miciek; Joanne Krasnoff; Ayan Elmi; Philip E Knapp; Brad Brooks; Erica Appleman; Sheetal Aggarwal; Geeta Bhasin; Leif Hede-Brierley; Ashmeet Bhatia; Lauren Collins; Nathan LeBrasseur; Louis D Fiore; Shalender Bhasin Journal: N Engl J Med Date: 2010-06-30 Impact factor: 91.245
Authors: Rebecca Vigen; Colin I O'Donnell; Anna E Barón; Gary K Grunwald; Thomas M Maddox; Steven M Bradley; Al Barqawi; Glenn Woning; Margaret E Wierman; Mary E Plomondon; John S Rumsfeld; P Michael Ho Journal: JAMA Date: 2013-11-06 Impact factor: 56.272
Authors: Molly M Shores; Daniel R Kivlahan; Tatiana I Sadak; Ellen J Li; Alvin M Matsumoto Journal: J Clin Psychiatry Date: 2009-07 Impact factor: 4.384
Authors: E Nieschlag; H M Behre; P Bouchard; J J Corrales; T H Jones; G K Stalla; S M Webb; F C W Wu Journal: Hum Reprod Update Date: 2004-08-05 Impact factor: 15.610
Authors: William D Finkle; Sander Greenland; Gregory K Ridgeway; John L Adams; Melissa A Frasco; Michael B Cook; Joseph F Fraumeni; Robert N Hoover Journal: PLoS One Date: 2014-01-29 Impact factor: 3.240
Authors: Rob F Walker; Neil A Zakai; Richard F MacLehose; Logan T Cowan; Terrence J Adam; Alvaro Alonso; Pamela L Lutsey Journal: JAMA Intern Med Date: 2020-02-01 Impact factor: 21.873
Authors: M Reza Sadaie; Mehdi Farhoudi; Masumeh Zamanlu; Nasser Aghamohammadzadeh; Atieh Amouzegar; Robert E Rosenbaum; Gary A Thomas Journal: Ther Adv Drug Saf Date: 2018-05-08
Authors: Michael W O'Reilly; Raoul C Reulen; Saket Gupta; Claire A Thompson; Rosemary Dineen; Eirena L Goulden; Gabriella Bugg; Harriet Pearce; Andy A Toogood; Neil J Gittoes; Rosalind Mitchell; Christopher J Thompson; John Ayuk Journal: Clin Endocrinol (Oxf) Date: 2016-07-25 Impact factor: 3.478